Retispec
Agent52 out of 100, Top 25%. Agent Readiness. Open the scores section.Agent Readiness: 52/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust80 out of 100, Top 25%. Data Trust. Open the scores section.Data Trust: 80/100. Top 25%. Measured by StartupHub.ai. Median 61.AI-powered eye exam for early detection of neurodegenerative diseases like Alzheimer's.
About
RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpec's proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimer's disease. RetiSpec is involved in multiple Alzheimer's and brain health studies in leading hospitals and research networks throughout North America.
Listed competitors
EyeGate is developing ocular drug delivery systems and diagnostics, but RetiSpec's specific focus on AI for neurodegenerative disease detection via retinal imaging is a key differentiator.
CogniLink also focuses on AI-driven diagnostics for neurological conditions, potentially using different imaging modalities or AI approaches.
Also in this space
AI-powered medical imaging software for improved workflow and image quality.
Shares HealthTech, MedTech
Changing the trajectory of human health, one baby at a time.
Shares HealthTech, MedTech
Digital pathology imaging technology and AI-driven precision pathology software.
Shares HealthTech, MedTech
Wearable devices and AI for continuous health monitoring and early disease detection.
Shares HealthTech, MedTech
Lunit is a medical AI company developing AI-powered solutions for cancer diagnostics and therapeutics.
Shares HealthTech, MedTech
AI-powered medical imaging analysis for faster diagnosis and treatment in healthcare.
Shares HealthTech, MedTech
Key facts
- Website
- retispec.com
- Headquarters
- Oulu, Finland
- Founded
- 2016
- Employees
- 33
- Total funding
- $11M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 26 Jul 2024 | Series A | $10M | iGan Partners |
| 1 Jun 2018 | Seed | $1M | |
| 30 Jun 2017 | Pre-Seed | $100K |
Tech stack
Detected on retispec.com, last scanned 3 Nov 2026. Run your own scan
- Observability
- Sentry
- CMS / Builders
- Wix
- Email provider
- Google Workspace
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
What does Retispec do?
RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimer's disease and other causes of cognitive decline. RetiSpec was recently selected from more than 75 global applicants to receive the Davos Alzheimer's Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.
Is Retispec trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Retispec is 80 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Retispec raised?
Retispec has raised a total of $11M in funding. The most recent round on record is Series A.
How many employees does Retispec have?
Retispec has approximately 33 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Retispec:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
